DexCom, Inc. (NASDAQ:DXCM) Given Average Rating of “Moderate Buy” by Brokerages

DexCom, Inc. (NASDAQ:DXCM) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-six brokerages that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $86.3043.

Several research analysts have recently weighed in on DXCM shares. Truist Financial restated a “buy” rating and issued a $82.00 price target (down previously from $94.00) on shares of DexCom in a research note on Monday, November 3rd. Robert W. Baird set a $82.00 price objective on DexCom in a report on Friday, October 31st. Royal Bank Of Canada decreased their target price on DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Evercore ISI started coverage on shares of DexCom in a report on Tuesday, November 25th. They set an “in-line” rating and a $68.00 price target on the stock. Finally, JPMorgan Chase & Co. reduced their price target on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Friday, October 31st.

Insiders Place Their Bets

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares in the company, valued at approximately $1,569,690.17. The trade was a 3.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard Alexander Collins sold 2,906 shares of the stock in a transaction on Friday, November 14th. The shares were sold at an average price of $59.05, for a total value of $171,599.30. Following the transaction, the director directly owned 35,088 shares in the company, valued at $2,071,946.40. The trade was a 7.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 7,866 shares of company stock valued at $448,177. Company insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Trust Co. of Vermont increased its position in shares of DexCom by 14.8% during the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after purchasing an additional 145 shares during the last quarter. CVA Family Office LLC grew its position in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares during the period. GAMMA Investing LLC increased its holdings in DexCom by 2.5% during the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after buying an additional 169 shares during the last quarter. IFP Advisors Inc increased its holdings in DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after buying an additional 178 shares during the last quarter. Finally, Inspire Investing LLC raised its position in DexCom by 6.1% in the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after acquiring an additional 180 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Down 1.4%

Shares of DexCom stock opened at $72.86 on Friday. The company has a 50-day simple moving average of $66.41 and a two-hundred day simple moving average of $71.16. The stock has a market capitalization of $28.42 billion, a PE ratio of 40.48, a price-to-earnings-growth ratio of 1.31 and a beta of 1.48. DexCom has a 52-week low of $54.11 and a 52-week high of $93.25. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.04. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.45 earnings per share. On average, analysts anticipate that DexCom will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.